Test Catalog

Test ID: SSTR2    
Somatostatin Receptor 2 (SSTR2), Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Aids in the identification of neuroendocrine tumors

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Somatostatin receptor 2 (SSTR2) is expressed in the secretory cells of the pancreas and the neurons of the central nervous system. SSTR2 is overexpressed in neuroendocrine tumors (NET) and can help predict response to targeted radiopeptide therapy. SSTR2 expression can also play a role in guiding imaging studies and treatment choice.

Interpretation Provides information to assist in interpretation of the test results

The positive and negative controls are verified as showing appropriate immunoreactivity. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request; contact 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Kiseljak-Vassiliades K, Xu M, Mills T, et al: Differential Somatostatin Receptor (SSTR) 1-5 Expression and Downstream Effectors in Histologic Subtypes of Growth Hormone Pituitary Tumors 3.1. Molecular and Cellular Endocrinology 2015;417:73–83

2. Brunner P, Jörg AC, Glatz K, et al: The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2017;44:468-475

3. Sizdahkhani S, Feldman M J, Piazza M G, et al: Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Scientific Reports 2017;7:40822

4. Shen Z, Chen X, Li Q, et al: SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males. Diagnostic pathology 2016;11(1):10